Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4392-4401
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4392
Table 3 Tumor response of different programmed cell death 1 inhibitor groups, n (%)
PD-1 inhibitor
CR
PR
SD
PD
P value
Tislelizumab2 (14.3)5 (35.7)4 (28.6)3 (24.1)0.927
Sintilimab1 (5.9)10 (58.8)5 (29.4)1 (5.9)
Camrelizumab6 (13.3)17 (37.8)14 (31.1)8 (17.8)
Toripalimab4 (14.3)12 (42.9)8 (28.5)4 (14.3)